Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals
NASDAQ | Common Stock
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States.
Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension.
The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases.
It has a collaborative research, development, and licensing agreement with DSM Biomedical.
Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 3, 22 | -0.27 Increased by +62.50% | -0.44 Increased by +38.64% |
| Aug 4, 22 | -0.32 Increased by +52.24% | -0.56 Increased by +42.86% |
| May 5, 22 | -0.66 Increased by +8.33% | -0.65 Decreased by -1.54% |
| Feb 24, 22 | 1.09 Increased by +237.97% | -0.67 Increased by +262.69% |
| Nov 4, 21 | -0.72 Decreased by -10.77% | -0.62 Decreased by -16.13% |
| Aug 4, 21 | -0.67 Increased by +19.28% | -0.64 Decreased by -4.69% |
| May 5, 21 | -0.72 Increased by +13.25% | -0.68 Decreased by -5.88% |
| Feb 25, 21 | -0.79 Increased by +17.71% | -0.76 Decreased by -3.95% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 22 | 36.13 M Increased by +23.25% | -26.83 M Increased by +32.41% | Decreased by -74.25% Increased by +45.16% |
| Jun 30, 22 | 33.31 M Increased by +22.53% | -19.37 M Increased by +49.93% | Decreased by -58.15% Increased by +59.14% |
| Mar 31, 22 | 29.84 M Increased by +29.89% | -35.89 M Increased by +14.47% | Decreased by -120.30% Increased by +34.15% |
| Dec 31, 21 | 114.67 M Increased by +364.55% | 45.53 M Increased by +198.69% | Increased by +39.71% Increased by +121.24% |
| Sep 30, 21 | 29.31 M Increased by +45.97% | -39.69 M Decreased by -0.11% | Decreased by -135.40% Increased by +31.42% |
| Jun 30, 21 | 27.18 M Increased by +50.75% | -38.69 M Increased by +19.71% | Decreased by -142.31% Increased by +46.74% |
| Mar 31, 21 | 22.97 M Increased by +12.92% | -41.96 M Increased by +14.58% | Decreased by -182.69% Increased by +24.36% |
| Dec 31, 20 | 24.68 M Increased by +0.11% | -46.14 M Increased by +16.21% | Decreased by -186.92% Increased by +16.30% |